Cellular immune response in infected mice to NSP protein encoded by the negative strand NS RNA of influenza A virus by O. Zhirnov P. et al.
Volume 6    Number 1     2019                                     Microbiology Independent Research Journal p 28-36 mir-journal.org
RESEARCH PAPER
Cellular immune response in infected mice to NSP protein encoded  
by the negative strand NS RNA of influenza A virus
Oleg P. Zhirnov1,2, Tatyana E. Konakova1, Darisuren Anhlan3, Stephan Ludwig3, Elena I. Isaeva1
1 N. F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Moscow, Russian Federation
2 The Russian-German Academy of Medical and Biotechnological Sciences, Moscow, Russian Federation
3 Institute of Virology, Westphalian Wilhelm University Münster, Münster, Germany
# Corresponding author: Oleg Zhirnov, e-mail: zhirnov@inbox.ru
Keywords: influenza virus, genome strategy, NSP protein, ambisense viruses
DOI: 10.18527/2500-2236-2019-6-1-28-36
Received December 30, 2018 Accepted March 13, 2019 Published June 10, 2019
ABSTRACT
Influenza A virus belongs to a family of enveloped viruses with an RNA genome of negative polarity consisting of 8 RNA segments. 
The transcription of this RNA genome results in the synthesis of positive-sense mRNAs that translate up to 16 unique viral pro-
teins with the help of splicing and translational shift mechanisms. The 8th NS segment encodes the NS1 protein (27 kDa), which 
is an active interferon antagonist, and the nuclear export protein NEP (14 kDa) through the standard negative polarity pathway. 
In addition, an alternative open reading frame for the synthesis of a third viral protein (NSP, negative-strand protein) by means 
of a direct translation of genome polarity RNA (the so-called positive polarity genome strategy) was identified in the NS segment. 
Since it is unknown as to whether the NSP protein can be synthesized in the infected organism post viral infection, the generation 
of spleen leucocytes specific to this protein was studied in mice after two sequential infections with influenza A viruses of H1N1 
and H3N2 subtypes. It was found that leucocyte clones specifically recognizing a peptide domain in the central region of the NSP 
protein (amino acid positions 82-119) were generated in mice infected with influenza A viruses. In silico prediction has shown 
strong major histocompatibility complex-1 (MHC-I) and MHC-II specific epitopes in this central domain of the NSP. Comparative 
analysis of the influenza H3N2 viruses circulating in humans during 1968-2018 has shown high NSP variability, which was similar 
to that shown for the hemagglutinin (HA) and neuraminidase (NA) proteins. The highest variability was found to be in the N- and 
C-terminal parts of the NSP. These observations suggest that synthesis of the NSP protein occurs in infected animals and further 
support a bipolar (ambisense) strategy of the RNA genome of human influenza A virus.
INTRODUCTION
Influenza A virus (Orthomyxoviridae family, alphainflu-
enzavirus genus) is an enveloped virus with an RNA ge-
nome that has a negative-sense strategy for replication 
and expression in infected cells. The virus genome con-
sists of 8  negative-sense RNA segments; each of them 
serves as a template for the synthesis (transcription) of 
the positive-sense mRNAs, which are translated in the 
infected cells to produce 16 viral proteins, using splicing 
and a translational frame shift [1, 2]. The eighth NS RNA 
segment encodes for two proteins by means of classical 
negative-sense strategy – the nonstructural protein NS1 
(27 kDa), which is an active interferon (IFN) antagonist, 
and nuclear export protein NEP (14 kDa) [1].
It was previously reported that an alternative pathway 
for the synthesis of the third viral protein by the direct 
translation of virion negative-sense vRNA is encoded in 
the NS segment as shown in Fig. 1 [3-5]. An open read-
ing frame (ORF) for an additional viral protein, the so-
called negative-strand protein (NSP), was identified in 
the NS segment of the overwhelming majority of human 
influenza A viruses [6]. Study of the evolution of the NSP 
gene over time by the method of multi-metric analysis of 
gene variability in different viral strains showed that the 
NSP gene appeared in a population of human influenza A 
viruses in the early twentieth century [6]. In the vast ma-
jority of avian influenza A viruses, the NSP gene in the NS 
segment is blocked by a series of nonsense stop codons. 
Based on the analysis of the primary structure of the NSP 
gene of various virus strains, the corresponding protein 
can be considered as transmembrane since it has two dis-
tinct hydrophobic domains at the N- and C-termini of the 
polypeptide molecule and one N-glycosylation site [4]. 
According to our previous results, the NSP gene of in-
fluenza A virus protein inserted into the insects’ baculovi-
rus genome (nuclear polyhedrosis virus) can be expressed 
in the virus-infected ovarian cells of the cabbage looper 
(H5 cell line) [7]. The synthesized protein had perinuclear 
localization and, possibly, was associated with the Golgi 
apparatus membranes due to its transmembrane proper-
ties. Recently, we have shown that the full-size RNA of 
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segment 8 (NS) of human influenza A/Aichi/2/68 (H3N2) 
virus can be recognized by the ribosomes of mammalian 
cells in vitro. This RNA was able to initiate the synthesis 
of 2 viral polypeptides with a molecular weight (MW) of 
23 and 13 kDa, which specifically reacted with antibodies 
specific to the NSP82-119 peptide representing the central 
part of the NSP protein of influenza A virus [8]. These re-
sults confirm that the vRNA of segment 8 of human in-
fluenza A virus has a messenger translation function that 
is in accordance with the concept of bipolar (ambisense) 
influenza A viral genome strategy. Currently, the sig-
nificance of the detected gene and the possibility of NSP 
protein expression during virus replication have not yet 
been established [9-12]. The importance of the positive-
polar gene in the influenza A virus has been proved by the 
fact that, since the beginning of the 20th century until 
the present time, this gene remains fully functional in the 
genome of human viral strains despite the pronounced 
drift variability of the viral genome [6]. It is not yet known 
how and in what cells the NSP protein of the influenza A 
virus can be synthesized, but over the course of its syn-
thesis in the host organism, specific humoral and/or cel-
lular response to this viral protein may be generated. This 
specific immune response will serve as the confirmation 
of the synthesis of this viral protein in the infected host 
organism. 
In order to check this hypothesis, we investigated the 
formation of the lymphocytes specific to the NSP82-119 
peptide, after the double infection of mice with influenza 
A virus.  
MATERIALS AND METHODS 
Viruses 
Influenza virus A/WSN/33 (H1N1) and the reassortant 
of A/Aichi/2/68 (H3N2) virus with A/WSN/33, contain-
ing one NS segment from A/WSN/33 virus and the 
rest of the genes from A/Aichi/2/68 (H3N2) (named as 
A/Aichi/2/68-WSN) were used in this study. The reas-
sortant A/Aichi/2/68-WSN (H3N2) was obtained by the 
reassortment method at the Gamaleya Scientific Re-
search Institute of Epidemiology and Microbiology. Both 
viruses were propagated in the allantoic cavity of 9-day-
old chicken embryos. 
Virus titration
The infectious titer of viruses was determined by the 
method of infectious foci formation in the Madin Dar-
by canine kidney (MDCK) cells, as described previously 
[6, 13]. The infectious activity of virus preparations was 
expressed in focus-forming units (FFU).
Production of recombinant NSP protein in bacterial 
cells 
For the synthesis of NSP protein in the E.  coli bacte-
rial system (BL21/DE3)pLysS, IPTG-inducible vector 
pET30a and the NSP gene sequence (amino acid posi-
tions 27-158) of the influenza A/WSN/33 (H1N1) virus 
strain (the GenBank accession number M12597.1) were 
used. In order to reduce the toxicity of the synthesized 
NSP protein in E. coli cells, the NSP gene sequence was 
altered in such a way that its translation resulted in the 
protein lacking the N-terminal hydrophobic peptide of 
26 amino acids. The shortened NSP gene was amplified 
by PCR using NSP (-sp)/Bgl/fo (tat aag atc tcc aag cga atc 
tct gta g) and NSPwsnR1/re (tat cga att cgg aac tga cat 
gac tct tga gg) primers adding two 6xHis sequences at 
each N and C ends of the NSP. The obtained NSP gene 
fragment was integrated into pET30a between the Bgl-II 
and Eco-R1 sites. Competent (BL21/DE3)pLysS cells were 
transformed with pET30a-NSP(-26)-his+ plasmid using 
transformation TSS buffer with the heat shock at 42℃ by 
the standard procedure. Positive colonies were collected 
post overnight cultivation in kanamycin Luria-Bertani 
(LB) medium. For NSP protein synthesis (calculated MW 
19.5 kDa), the resulting culture was mixed with 4 parts of 
LB, maintained for 1.5 h at 37℃, and after the addition of 
IPTG to a final concentration of 1 mM incubated for 3.5 h 
at 25℃. The cells were pelleted, destroyed by sonication, 
and centrifuged at 12,000 g for 20 min at + 4℃. The pre-
cipitates were dissolved in 5M urea solution prepared 
with 50 mM phosphate buffer (PBS) (pH 7.3) containing 
0.3% of NP-40 detergent and protease inhibitors cock-
tail (Calbiochem). Protein purification was performed on 
Ni-NTA agarose (Qiagen) according to the manufactur-
er’s protocol. The elution of the protein was carried out 
with buffer containing 0.3 M NaCl, 0.4 M imidazole, and 
50 mM PBS (pH 6.0). NSP protein fraction was dialyzed 
against 50 mM PBS (pH 7.3). The NSP protein content in 
the obtained preparations was about 60-80%. 
Infection of mice with influenza A viruses
The Balb/c mice (weighing 10-12 g) were used for the ex-
periments. All of the animal experiments were approved 
by the Ethics Committee of the Gamaleya Scientific Re-
search Institute of Epidemiology and Microbiology. Ex-
perimental procedures were performed in accordance 
with the Guidelines for the Care and Use of Laboratory 
Fig. 1. The scheme of transcription and translation of the NS vRNA 
segment of influenza A virus.
Schematic representation of genes in the NS segment of influenza 
A/Aichi/2/68 (H3N2) virus is shown. vRNA – negative-sense virion 
RNA; cRNA – positive-sense complementary RNA (replicative form). 
Numbers indicate the positions of the nucleotides from the 5’-end 
of the vRNA. The exons of the genes encoding for the NS1, NEP and 
NSP proteins are indicated by arrows. The broken line shows the 
splicing zone of the mRNA NEP gene. The grey field indicates the 
overlapping region of three viral genes: NS1, NEP, and NSP.
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Animals. All of the painful procedures were performed 
under anesthesia. Animals were infected first with influ-
enza A/WSN/33 (H1N1) virus, and in 4 weeks with the re-
assortant virus A/Aichi/2/68-WSN (H3N2). Mice were in-
fected intranasally by inhaling virus aerosol (105 FFU/ml) 
obtained by the sonication of virus suspension for 2 min 
using a Musson-1 ultrasonic nebulizer (Russia). The in-
fective dose was 10-100 FFU/mouse. On the 21st day after 
infection, the blood sera of animals were collected. The 
presence of specific antibodies to the influenza virus was 
determined using the hemagglutination inhibition assay 
(HAI) carried out according to the standard procedure. 
To determine the influenza virus in the mouse lungs, the 
broncho-alveolar washes were collected by washing the 
lungs with 1 ml of PBS solution through the trachea on 
the 3rd day after the second infection. The presence of 
the virus in the washes was determined by virus titration 
according to the method of infectious foci formation in 
the MDCK cells, as described hereinabove.
Fractionation of leukocytes from the spleen of mice 
infected with influenza virus 
The spleen of each mouse was mechanically disrupted to 
obtain a single cell suspension and clarified by centrifu-
gation at 170 g for 10 min (Eppendorf 5804/R, FL 100 ro-
tor). The level of viable cells in the supernatant was not 
lower than 80% according to trypan blue staining. The 
cells from each mouse were added to a 96-well plate in 
the amount of 1.1-1.6 x 106  cells/well and cultured for 
24 h at 37℃ in RPMI 1640 medium supplemented with 
10% of fetal bovine serum (Gibco BRL). Then, the stud-
ied preparations: peptide NSP82-119 (1 μg/ml), NSP protein 
(2.5 μg/ml), or virus A/Aichi/2/68-WSN (H3N2) with the 
multiplicity of infection of 0.01 FFU/cell were added. Bo-
vine serum albumin (BSA) with the final concentration 
of 3 μg/ml was added to the control cells. After the sub-
sequent incubation for 20  h, cells from each well were 
harvested and pelleted. RNA was isolated from the pel-
lets followed by analyzing the level of IFNγ mRNA and 
ribosomal 28S RNA using real-time PCR (RT-PCR). 
Determination of the IFNγ level in leucocytes 
by RT‑PCR 
In order to study the cellular immunity of mice after 
double infection with influenza viruses, the degree of 
leucocyte immune reactivity to NSP protein in the mice 
was assessed. The polypeptide of 38  amino acids with 
the sequence CTSSSVCPGREGSGEISPTIVPSSVKAL-
SNIRVSSRSK corresponding to the central part of the 
NSP protein of influenza A/WSN/33 (H1N1) (amino acid 
positions 82-119) and common for the most viral strains, 
was synthesized at Quyun (China) (purity 90%) and was 
used as a target antigen. The first amino acid leucine (L) 
was replaced with cysteine (C) for conjugation with the 
keyhole limpet hemocyanin (KHL) carrier protein during 
immunization [7]. The degree of the leukocyte’s reactiv-
ity was evaluated by the level of mRNA of IFNγ measured 
by RT-PCR with the primers specific for murine IFNγ 
(Table 1) after the contact with polypeptide NSP82-119, pu-
rified recombinant protein NSP or influenza virus. The 
RNA from leukocytes was isolated using the Proba-NK 
kit according to the manufacturer’s protocol (DNA-Tech-
nology LLC, Russia). The cDNA corresponding to this 
mRNA was synthesized using a random primer accord-
ing to the Reverta-1 kit protocol (AmpliSense LLC, Rus-
sia). The obtained cDNA was used for PCR with primers 
to the IFNγ gene. To normalize the obtained values for 
IFNγ mRNA, the level of murine ribosomal 28S RNA was 
evaluated simultaneously using the primers specific for 
ribosomal 28S RNA (Table  1). The mRNA IFNγ content 
was expressed in arbitrary units (AU), normalized by the 
number of ribosomal 28S RNA in the analyzed sample.
Electrophoresis in polyacrylamide gel and Western 
blot (WB) analysis  
The proteins were fractionated in a polyacrylamide gel 
(PAAG) containing sodium dodecyl sulphate (SDS). Then, 
the proteins were transferred from the gel to a nitrocel-
lulose membrane Protran 0.45 μm (Schleicher & Schull) 
by semi-dry method [13]. The membrane was washed 
with PBS, incubated for 2 h in 3% skim milk, and then 
overnight at +5℃ in PBS containing 0.5% BSA (Sigma) 
and specific primary antibodies. The primary antibodies 
were obtained in guinea pig against NSP82-119 oligopep-
tide according to the procedure described earlier [7]. The 
membrane was then washed with PBS and treated with 
species-specific antibodies conjugated with horseradish 
peroxidase (Dako, USA), followed by the identification of 
positive components by chemiluminescence (ECL) with a 
super-substrate (Pierce, USA), as previously described [13]. 
RESULTS 
Variability of the NSP gene in human influenza 
H3N2 viruses. 
At first, we estimated the variability of the NSP gene 
and the corresponding protein over the course of 
Table 1. Primers used for the detection of mRNA of IFNγ and ribosomal mouse 28S RNA
Primer assignment Primer structure
1. Primer for the synthesis of 28S RNA fragment (F) 5’-GCTCATTAAATCAGTTATGGTTC-3’ 
2. Primer for the synthesis of 28S RNA fragment (R) 5’-GAGGTTATCTAGAGTCACCA-3’
3. Probe for the detection of 28S RNA P [R6G]-CGCTCGCTCCTCTCCTACTTGG-[BHQ2]
4. Primer for the synthesis of IFNγ fragment (F) 5’-GCCTAGAAAGTCTGAATA-3’  
5. Primer for the synthesis of IFNγ fragment (R) 5’- CCAGATATCCAAGAAGAG -3’
6. Probe for the detection of IFNγ P [R6G]-TCTTCCACATCTATGCCACTTGA-[BHQ2]
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natural evolution of influenza virus. For this purpose, 
the primary NSP gene structure of influenza viruses of 
H3N2 subtype circulating in humans from 1968 (when 
this viral subtype emerged) to the present time was 
analyzed. The dynamics of mutation occurrence in the 
NSP protein is shown in Fig.  2. It is evident that the 
primary structure of the NSP protein has changed sig-
nificantly, and mainly the N- and C-terminal regions of 
the protein were affected, whereas in the central part 
only minor changes occurred. To assess the rate of vari-
ability, the coefficient of variation (CV) of the protein 
was calculated. The CV shows the number of mutations 
per 100  amino acids in the protein per year (Table  2). 
The CV of NSP protein was 0.34, which is similar to the 
CV of hemagglutinin (HA) and neuraminidase (NA)  – 
0.4 – that are the most variable surface proteins of in-
fluenza virus. The obtained results also suggest that 
the significant variability of the N-terminal NSP region 
(Fig. 2) was determined by the changes in the NSP gene 
sequence leading to multiple mutations in the NSP pro-
tein but not in the NEP and NS1 proteins since both of 
them have much lower variability – CV 0.08 and 0.26, 
respectively (Table 2). The presented data show that the 
NSP protein is exposed to significant evolutionary vari-
ability probably due to its adaptation to tissue factors, 
and/or viral proteins with which it might interact and 
Fig. 2. The mutations accumulation dynamics in the NSP protein of the human influenza H3N2 viruses in the course of the natural evolu-
tion from 1968 to 2018. 
The chart was composed using the influenza virus NS gene sequences of viruses isolated in the period from 1968 to 2018 and presented 
in the GenBank database. 





The number of analyzed 
sequences over 50 years
Number of detected
mutant positions
Coefficient of variation 
(CV)a
PB1 86,000 13,215 23 0.05
PB2 87,000 13,201 34 0.08
PA 85,000 13,183 47 0.1
HA 75,000 19,639 139 0.4
NP 56,000 13,505 58 0.2
NA 56,000 17,147 114 0.4
M1 27,000 16,145 12 0.09
NS1 27,000 13,847 34 0.26
M2 14,000 15,438 7 0.14
NEP 14,000 13,739 5 0.08
NSP 25,000 14,331 37 0.34
a The evolutionary variability of the protein was assessed by the CV, which was determined by the number of amino acid positions in a separate 
viral protein that underwent mutations in the human influenza A/H3N2 virus strains from 1968 to 2018. CV was calculated as the total number 
of mutant amino acid positions in each protein in one year per 100 amino acids. The sequence data were obtained from GenBank. 
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change concurrently or as a result of escape from the 
host immune factors. 
In silico analysis of the immunological domains 
in the NSP protein structure 
The results of the computational analysis of the predict-
ed T- and B-cell humoral epitopes based on the primary 
structure of influenza A virus NSP protein are shown in 
Fig. 3. T-cell epitopes were identified using software for 
predicting the binding of peptide domains to the recep-
tors of the major histocompatibility complex-1 (MHC-I) 
[14] and MHC-II [15]. B-cell humoral epitopes were eval-
uated based on the antigenic index algorithm according 
to Jameson and Wolf [16]. As shown in Fig. 3, three T-epi-
tope regions are predicted in the NSP protein – in amino 
acid positions 10-25, 40-50, and 85-110 (Fig. 3f, g). B-cell 
epitope regions are predicted by the software in three 
sites – amino acid positions: 70-80, 85-95, and 110-120 
(Fig. 3e) – which are characterized by low hydrophobicity 
(Fig. 3d) and partially overlap with one MHC-II epitope 
(Fig. 3g). These results indicate that the NSP82-119 peptide 
used in this study includes two neighboring epitopes 
recognized by both MHC-I (Fig. 3f) and MHC-II (Fig. 3g) 
receptors. The presence of such epitopes in the NSP82-119 
molecule could provide the immune response of both B- 
and T-cell types in virus-infected mice. 
The recombinant NSP protein 
The identity of the recombinant NSP protein expressed 
in E. coli BL 21(DE3)pLysS cells was analyzed by the 
Fig. 3. The domain structure of influenza A/WSN/33 (H1N1) virus NSP protein. 
The primary structure of the NSP protein (MW 19 kDa), compiled on the basis of nucleotide sequence of influenza A/WSN/33 virus (H1N1) 
NSP gene: (a) amino acid sequence of the NSP protein is presented in a single letter code; (b) hydrophobicity profile as determined by the 
Kyte-Doolittle method; (c, d) the areas of α-helices and β-sheets, respectively, identified by the Chou-Fasman method; (e) B-cell humoral 
epitopes predicted by the Jameson-Wolf antigenicity index method; (f, g) T-cell epitopes predicted by the algorithm of interaction with 
MHC-I and MHC-II receptors. The ordinate axis shows the number of MHC-I (f) alleles capable of recognizing each of these epitopes, and 
the affinity index of the interaction of 12 amino acids epitopes with MHC-II in the NSP molecule (g). The frames show the amino acids 44-51 
and 82-119 positions, corresponding to the peptides studied in the paper published by Zhong et al. [17] and in the present study, respectively.
Fig. 4. Analysis of the recombinant NSP protein by the Western blot. 
The recombinant influenza virus A/WSN/33 (H1N1) NSP protein, flanked on the N and C termini by 6xHis peptides, was expressed in com-
petent BL21 (DE3) pLysS E. coli cells. After purification on the Ni-NTA agarose, it was analyzed by electrophoresis in PAAG with subsequent 
Western blot analysis. Lanes 1, 3 – control preparation of non-transformed BL21 (DE3) pLysS cells; lanes 2, 4 – preparation of NSP protein 
purified from BL21(DE3) pLysS cells transformed with pET30a-NSP(-26)-his+. Tetra-His antibodies (lanes 1, 2) and antibodies to NSP82-119 
peptide (lanes 3, 4) were used for primary staining. The positions of the marker proteins are shown on the left, with indicated MW (kDa).
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Western blot analysis with specific antibodies obtained 
for NSP82-119 peptide and for the 6xHis oligopeptide. The 
NSP protein of A/WSN/33 virus containing two 6xHis 
peptides on the N- and C-termini was synthesized ac-
cording to the method described in the Materials and 
Methods. As shown in Fig.  4, the NSP protein synthe-
sized in bacterial cells reacted with both anti-NSP82-  119 
and anti-6xHis antibodies (Fig. 4, lane 2 and 4). These re-
sults confirm that the recombinant protein expressed in 
E. coli cells corresponds to the NSP protein of influenza 
A/WSN/33 virus.
Sequential infection of mice with two influenza 
viruses of H1N1 and H3N2 subtypes
The preliminary attempts to measure the distinct cellu-
lar immune response to the NSP protein after a single 
influenza infection of mice were unsuccessful. In order to 
enhance the expected immune response, the mice were 
infected twice with two influenza strains causing the dis-
ease with an interval of 30 days. For this purpose, the ani-
mals were infected first with influenza A/WSN/33 (H1N1) 
virus carrying NS gene encoding NSP protein (18  kDa) 
[4]. After the recovery from the primary infection, the 
animals were reinfected with heterologous reassortant 
A/Aichi/2/68-WSN (H3N2) virus, in which the NS genom-
ic segment was replaced by that of A/WSN/33 virus. 
The level of the disease after primary infection with 
A/WSN/33 virus was assessed by measuring the loss of 
body weight, a parameter that is known to reflect the mor-
bidity. As shown in Fig. 5, the slowdown in weight gain 
was observed in mice from the 3rd to 8th day after infec-
tion by aerosol influenza virus compared to the uninfect-
ed mice. The increase of animal weight was recovered by 
the 15th day post infection. In the animals’ sera, obtained 
on the 21st day post immunization, the anti-HA antibod-
ies against A/WSN/33 virus were detected with titers that 
ranged from 1/40 to 1/160 (the data are not shown) as 
measured by HAI assay. These data confirm that all of the 
animals were properly infected with the virus. 
Fig. 5. The dynamics of the mouse weight changes upon infection 
with the influenza viruses. 
BALB/c mice were infected (day 0) with A/WSN/33 (H1N1) virus. 
On the 30th day, the mice were reinfected with the reassortant 
A/Aichi/2/68-WSN (H3N2) virus carrying the NS gene of A/WSN/33 
(H1N1). The arrow shows the day of reinfection. Each mouse was 
weighed during the observation period. The body weight curves for 
non-infected (▲) and infected (●) groups of mice are shown. The 
data are presented as M±SD. 
Four weeks after the first infection, the animals were re-
infected by the aerosol administration of a sublethal dose 
of A/Aichi/2/68-WSN (H3N2) reassortant. As in the case 
of primary infection, the animals showed a slowdown of 
weight gain confirming the infection process. The virus ti-
ters measured in the bronchopulmonary washes on the 3rd 
day post reinfection, varied in the range of 102–104 FFU/ml 
(data not shown). These results confirmed the development 
of productive virus infection after the second infection. 
On the 5th day after boost immunization, mice were 
sacrificed, the spleen was removed and processed to iso-
late the leukocyte fraction, in which the level of sensiti-
zation to NSP82-119 peptide or to NSP protein was tested. 
The NSP‑dependent immune reactivity of 
leukocytes obtained from the infected animals 
One of the methods for assessing the cellular immune re-
sponse after viral infection in animals is the determina-
tion of immune leukocytes that are measured by the level 
of IFNγ induced by the leucocytes of infected animals ex-
posed in vitro to the viral proteins or their peptides. The 
level of IFNγ can be assessed by the measurement of the 
corresponding mRNA by quantitative RT-PCR [18]. The 
leucocytes of infected mice were sensitized with NSP82-119 
peptide and the level of IFNγ mRNA was determined by 
RT-PCR. In parallel, leukocytes were sensitized with two 
preparations of purified NSP protein and with the whole 
virus. As shown in Fig. 6, the level of IFNγ induction in 
response to the stimulation of leukocytes by NSP82-119 
peptide – 2.3 AU – was significantly higher (p<0.05) than 
the values obtained for the control leukocytes stimulated 
with BSA (0.7 AU). The amount of IFNγ induced in re-
sponse to the stimulation of leukocytes by both recom-
binant protein NSP preparations was even higher (12.0 
Fig. 6. The levels of IFNγ mRNA in leucocytes of the infected mice 
stimulated by the target antigens. 
Leukocytes were isolated from the spleens of infected mice and sensi-
tized with: (1) BSA; (2) NSP82-119 oligopeptide; (3, 4) recombinant NSP 
protein from two different batches of isolation, respectively; (5) in-
fluenza A/Aichi/2/68-WSN. The bars show the values of mRNA in AU 
for each of 4 mice. The mean values for the group are shown above the 
columns (M±SD). Mock cells – leucocytes obtained from uninfected 
mice. The significance of the differences between the groups was 
evaluated by the Student’s t-test.  
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and 7.8 AU, p<0.01). The highest levels of expression of 
IFNγ (30.8 AU) were found in leukocytes sensitized by the 
virus reflecting the cumulative effect of epitopes present 
in the target antigens on peptide, recombinant protein 
and whole virus.
The control testing of IFNγ induction by the leuko-
cytes in non-infected animals sensitized with NSP82-119 
peptide did not show the reliable induction of IFNγ 
(0.06 AU, p>0.05) (Table 3). A slight (0.78 AU) increase 
in IFNγ induction after stimulation of leukocytes of un-
infected mice with recombinant NSP protein was com-
parable to the response to the unspecific stimulation of 
leucocytes with BSA (0.7 AU) that is most likely due to 
the residual impurity of bacterial proteins in the NSP 
protein preparation. A significant induction of IFNγ upon 
stimulation of leukocytes by the virus quite logically re-
flects the primary immune response of the splenocytes 
to virus infection.
Table 3. Level of IFNγ induction in the splenocytes of uninfected 
mice 
Antigens used for 
stimulation 





1. mock  0.04 ± 0.02    — 
2. NSP82-119  0.06 ± 0.02    2 versus 1, p> 0.05 
3. NSP  0.78 ± 0.26    3 versus 1, p<0.05 
4. A/Aichi/2/68-WSN  14.50 ± 5.1    4 versus 1, p<0.01 
 The levels of IFNγ mRNΑ expressed in AU determined in leucocyte 
samples obtained from uninfected mice (4 per group), sensitized with: 
(1) intact splenocytes (mock); (2) NSP82-119 peptide, (3) recombinant 
NSP protein; (4) A/Aichi/2/68-WSN virus. The data are presented as 
M±SD. The statistical significance of the differences is estimated by 
the Student’s t-test.
The obtained results show that the development of 
influenza infection in mice stimulated the generation of 
sensitized white blood cell clones, which recognize the 
epitopes of viral proteins, including the NSP protein, and 
induce the production of IFNγ. 
DISCUSSION 
An extended ORF with ATG start and TAG stop codons of 
a full gene, and structural elements for recognition by ri-
bosomes was revealed in the smallest NS segment of the 
influenza A virus genome besides the NS1 and NEP genes 
[8]. The main feature of the ORF of NSP gene is that it 
is located in the negative-sense RNA segment, in con-
trast to the ORF of NS1 and NEP, which are known to be 
of positive polarity, complementary to the vRNA (Fig. 1). 
The special polarity of the NSP gene suggests a specific 
mechanism of its expression, which should be different 
from that of other viral proteins. It can be assumed that 
there is a direct translation of a free negative-sense NS 
vRNA in infected cells prior to its encapsidation by the 
nucleoprotein (NP). NP protein forms viral ribonucleo-
protein (RNP) complexes (nucleocapsids) with vRNA and, 
probably, acts as a negative translational regulator, clos-
ing the access of ribosomes to vRNA. The mechanism of 
positive regulation through the viral NS1 protein, which 
can enhance the translation of genomic RNA in infect-
ed cells, cannot be ruled out [19-21]. It is possible that 
cellular factors play a decisive role in the NSP expression 
and determine the tissue tropism of this protein synthe-
sis in an infected organism [22]. Finally, an alternative 
specific mechanism of a subgenomic mRNA/NSP synthe-
sis on the viral cRNA template in flu virus-infected cells 
also cannot be excluded. 
The assumption of direct NS vRNA translation is 
consistent with recent observations that showed the 
ability of the virion full-length NS RNA of influenza 
A/Aichi/2/68 (H3N2) virus to be effectively translated 
in vitro by mammalian cell ribosomes to form a 23 kDa 
and a 13 kDa polypeptides that specifically reacted with 
antibodies to the NSP82-119 peptide in immune precipita-
tion reaction [8]. This result suggests the possibility of a 
specific translation of the NS negative polarity RNA of 
influenza virus in infected host cells. 
The data obtained in the present study most likely 
indicate the generation of a specific cellular immune 
response to the viral NSP protein in mice infected with 
influenza A virus. This conclusion implies the formation 
of NSP protein (or its components) during viral replica-
tion in the body of infected animals. Indirect proof of 
the expression of the NSP gene was recently obtained in 
experiments with the recombinant influenza A/Puerto 
Rico/8/1934 (A/PR/8) virus containing a chimeric NSP 
gene with the expression reporter in mice [23]. The re-
sults of our study are also consistent with the observa-
tions of Zhong et al. [17], who examined the immune 
profile of mouse leukocytes after infection with A/PR/8 
(H1N1) virus. The authors found leukocyte clones react-
ing with GGLPFSLL peptide, denoted by the authors as a 
“hypothetical peptide”. It is important to mention that 
both the NSP82-119 and the GGLPFSLL peptide, identical 
to the 44-51 amino acid positions of the A/WSN/33 NSP, 
correspond to the T-cell epitopes predicted in the NSP 
protein structure (Fig.  3g, f). Therefore, these results 
confirm the expression of the NSP gene in an infected or-
ganism, and the presence of T-cell epitope in the central 
part of the encoded NSP protein.
Based on the available data, it remains a challenge to 
determine the level of synthesis and tissue localization 
of NSP protein (or its products) in the infected animals. 
Moreover, the earlier attempts to detect mature NSP 
protein in vitro in cell culture infected with influenza A 
virus were unsuccessful [23], (Arikainen A. et al., Does 
segment 8 of influenza A virus encode a negative-strand 
polypeptide? 4th Influenza ESWI Conference, Malta 
2011, abstract B305P, 179). The difficulties of the NSP 
protein detection may be due to its rapid proteolysis with 
the formation of short functional peptides of the kinin 
type. It is possible that the expression of the NSP gene 
may be limited to certain types of cells that depend on 
specific factors present only in certain tissues of the host 
organism.
The important question is how the new ambipolar 
NSP gene could emerge in the genome of influenza A vi-
rus. The appearance of ambipolar gene suggests the pos-
sibility of the regulation of expression of the ambisense 
genes in RNA molecule by the rules that are currently 
unknown (or by the reverse determination rule). The 
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presence of such a region in the center of the NSP gene 
is marked with grey field (Fig. 1). The other two sites of 
the NSP gene overlap with either the NEP gene (at 5’ end) 
or with NS1 (at 3’ end). It is quite possible that a certain 
gene in the virus genome can predetermine the mecha-
nism of the ambipolar gene emergence and its proper-
ties. It is assumed that in the absence of determination 
mechanism, random mutations are accumulated, leading 
to the emergence of a new functionally semantic gene, 
followed by selection. The probability of such an event 
is low, given the ambipolar overlapping of several genes, 
when changes in one gene lead to changes in the linked 
ambipolar genes. In this case, the variability and selec-
tion of mutations should be linked together in three viral 
genes: NS1, NEP, and NSP. 
The conclusion based on the obtained results may be 
important for the classification of influenza viruses. It 
raises the question of the existence of an additional ge-
nus in the Orthomyxoviridae family, with the ambisense 
expression of the viral genome in the process of its life 
cycle, such as the representatives of known viral bipolar 
genera of phlebo-, tospo-, arena-, and tenuiviruses [24]. 
While the direct product of the NSP gene is not identi-
fied in infected cell cultures or human/animal organisms, 
the question of classification remains open so far. At the 
same time, the preservation of a functional NSP gene in 
a population of human influenza viruses for more than 
100 years indicates the importance of this gene for the 
hypothetical group of ambisense influenza viruses [6]. It 
is noteworthy that the pronounced evolutionary variabil-
ity of the NSP protein, similar to that of the most variable 
viral proteins HA and NA, did not cause nonsense mu-
tations forming stop codons that would destroy the NSP 
gene supporting the idea of the biological determinism 
of this gene. 
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